RxDoctor Payments Data

Nivea Ribas, MD

Neurology · Miami Lakes, FLNPI 1699773895

Payments from drug & device makers

$106,304in general payments, 2019–2025

Across 416 payments — averaging $255.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$97K
  • UCB, Inc.$2K
  • GE HealthCare$674
  • AbbVie$582
  • Pfizer$549
  • Amneal Pharmaceuticals LLC$510
  • plus $5K from 38 others

What the payments were for

  • Speaking & faculty fees$671%
  • Food & beverage$9,00699%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,304 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$63,236
Medicare patients
116
Services billed
415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5017$430,423
Gamunex-CImmune Globul G/Gly/Iga Avg 4626$270,191
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5035$267,978
NamzaricMemantine Hcl/Donepezil Hcl220$172,557
Avonex Pen (4 Pack)Interferon Beta-1a14$116,039
NuplazidPimavanserin Tartrate23$111,540
Nurtec OdtRimegepant Sulfate57$105,657
Rivastigmine371$64,907
KeppraLevetiracetam32$42,846
Aimovig AutoinjectorErenumab-Aooe22$39,463
TrileptalOxcarbazepine24$34,851
BriviactBrivaracetam23$34,586
RytaryCarbidopa/Levodopa42$32,616
ExelonRivastigmine23$31,634
NeuproRotigotine21$27,626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$16$270,19126 claims
AbbVieNamzaric$582$172,557220 claims
PfizerNurtec Odt, Lyrica, Dilantin$549$127,335109 claims
Acadia Pharmaceuticals IncNuplazid$250$111,54023 claims
UCB, Inc.Briviact, Neupro, Vimpat$2,037$80,07862 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$510$35,42190 claims
NovartisExelon$143$31,63423 claims
Sunovion Pharmaceuticals Inc.Aptiom$64$13,28511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami Lakes

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →